版本:
中国

BRIEF-Aimmune Therapeutics enrolls first patient in late-stage trial of its peanut allergy drug

May 11 Aimmune Therapeutics Inc-

* Aimmune Therapeutics enrolls first patient in ramses (arc007), a phase 3 clinical trial of ar101 for the treatment of peanut allergy

* Aimmune Therapeutics Inc - trial follows same up-dosing and maintenance protocol as aimmune's ongoing phase 3 palisade trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐